Table 1 Prevalence and disease associations of high-risk PRS for six diseases in MGBB overall and by reported race
From: Development of a clinical polygenic risk score assay and reporting workflow
Disease | High risk (%)a | OR overall | OR white | OR Black | OR Asian | OR Other/Unknown |
---|---|---|---|---|---|---|
OR (95% CI)b (n/n, n/n)c | OR (95% CI)b (n/n, n/n)c | OR (95% CI)b (n/n, n/n)c | OR (95% CI)b (n/n, n/n)c | OR (95% CI)b (n/n, n/n)c | ||
BrCa | 8.6 | 2.38 (2.07–2.73) (286/1,400, 1,427/16,606) | 2.39 (2.07–2.76) (270/1,156, 1,318/13,495) | 2.24 (0.97–5.15) (7/73, 43/1004) | 0.51 (0.07–3.9) (1/33, 24/405) | 2.35 (1.08–5.1) (8/138, 42/1,702) |
CRCa | 5.4 | 2.37 (1.74–3.24) (46/1,913, 346/34,117) | 2.29 (1.65–3.19) (41/1,646, 312/28,717) | 4.11 (1.17–14.48) (3/83, 15/1706) | 0 (0–NaN) (0/35, 7/744) | 3.30 (0.73–14.88) (2/149, 12/2,950) |
PrCa | 13.1 | 2.22 (1.98–2.48) (498/1,698, 1,693/12,813) | 2.31 (2.05–2.59) (468/1,448, 1,544/11,017) | 1.39 (0.74–2.59) (14/71, 74/521) | 2.58 (0.5–13.28) (2/36, 6/279) | 1.41 (0.78–2.58) (14/143, 69/996) |
AFib | 8.3 | 2.37 (2.12–2.64) (450/2,589, 2,282/31,101) | 2.40 (2.14–2.69) (422/2,179, 2,101/26,014) | 1.47 (0.72–3.01) (9/137, 71/1590) | 2.00 (0.57–7.03) (3/62, 17/704) | 2.28 (1.32–3.94) (16/211, 93/2,793) |
CAD | 9.8 | 1.86 (1.69–2.05) (562/3,018, 2,991/29,851) | 1.91 (1.73–2.12) (503/2,459, 2,680/25,074) | 1.41 (0.86–2.29) (21/177, 125/1484) | 3.96 (1.79–8.76) (9/51, 31/695) | 1.47 (0.97–2.22) (29/331, 155/2,598) |
T2D | 8.4 | 1.75 (1.57–1.95) (439/2,612, 2,924/30,447) | 1.93 (1.71–2.17) (367/2,284, 2,159/25,906) | 1.21 (0.7–2.09) (18/57, 358/1374) | 1.07 (0.37–3.08) (4/49, 52/681) | 1.58 (1.14–2.19) (50/222, 355/2,486) |